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Introduction: The immune system plays a major role in cancer progression. In solid tumors, 5-40 % of the tumor
mass consists of tumor-associated macrophages (TAMs) and there is usually a correlation between the number of
TAMs and poor prognosis, depending on the tumor type. TAMs usually resemble M2 macrophages. Unlike
M1-macrophages which have pro-inflammatory and anti-cancer functions, M2-macrophages are immunosuppressive,
contribute to the matrix-remodeling, and hence favor tumor growth. The role of TAMs is not fully understood in
breast cancer progression.
Methods: Macrophage infiltration (CD68) and activation status (HLA-DRIIα, CD163) were evaluated in a large cohort
of human primary breast tumors (562 tissue microarray samples), by immunohistochemistry and scored by
automated image analysis algorithms. Survival between groups was compared using the Kaplan-Meier life-table
method and a Cox multivariate proportional hazards model. Macrophage education by breast cancer cells was
assessed by ex vivo differentiation of peripheral blood mononuclear cells (PBMCs) in the presence or absence of
breast cancer cell conditioned media (MDA-MB231, MCF-7 or T47D cell lines) and M1 or M2 inducing cytokines
(respectively IFN-γ, IL-4 and IL-10). Obtained macrophages were analyzed by flow cytometry (CD14, CD16, CD64,
CD86, CD200R and CD163), ELISA (IL-6, IL-8, IL-10, monocyte colony stimulating factor M-CSF) and zymography
(matrix metalloproteinase 9, MMP-9).
Results: Clinically, we found that high numbers of CD163+ M2-macrophages were strongly associated with fast
proliferation, poor differentiation, estrogen receptor negativity and histological ductal type (p<0.001) in the studied
cohort of human primary breast tumors. We demonstrated ex vivo that breast cancer cell-secreted factors modulate
macrophage differentiation toward the M2 phenotype. Furthermore, the more aggressive mesenchymal-like cell line
MDA-MB231, which secretes high levels of M-CSF, skews macrophages toward the more immunosuppressive M2c
subtype.
Conclusions: This study demonstrates that human breast cancer cells influence macrophage differentiation and that
TAM differentiation status correlates with recurrence free survival, thus further emphasizing that TAMs can similarly
affect therapy efficacy and patient outcome.Introduction
Metastasis is often explained with the ‘seed and soil’ the-
ory. Conceptually, it implies that the cancer cell (seed)
undergoes epithelial to mesenchymal transition (EMT),
invades vessels, becomes a circulating tumor cell (CTC),
migrates, extravasates, undergoes mesenchymal to* Correspondence: sofia.sousa@uef.fi
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article, unless otherwise stated.epithelial transition, and eventually colonizes distant
sites as a disseminating tumor cell (DTC). ‘Soil’ relates
to tumor microenvironment elements which contribute
to these processes, making the distant sites permissive to
colonization by CTCs or DTCs [1].
The immune system is a major player in the cancer
cell/tumor microenvironment crosstalk. In solid tumors,
5−40 % of the tumor mass consists of tumor-associated
macrophages (TAMs). Approximately 80 % of the publi-
cations in this field report an association between TAMsis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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polarization is a continuum that spans two extremes
from the classically activated M1 macrophages to the al-
ternatively activated M2 macrophages. M1 macrophages
derive from interferon γ (IFN-γ) or lipopolysaccharide
(LPS) stimuli and secrete inflammatory cytokines (e.g.,
IL-6, IL-12, reactive oxygen species (ROS), reactive ni-
trogen species (RN) and TNF-α). The validated surface-
markers of human M1 macrophages include high levels
of CD14 and CD16, CD64, CD86 and HLA-DRα [4, 5].
M2 macrophages, can be further divided into M2a, M2b
and M2c macrophages. M2a macrophages arise from IL-
4 or IL-13 stimuli and release matrix-remodeling cyto-
kines. Elevated expression of CD200R and CD86 is a
validated phenotypic marker of M2a macrophages [4, 5].
M2b macrophages result from the recognition of im-
mune complexes in combination with IL-1β or LPS
stimuli and like M2a macrophages, they are involved
in wound healing. The immunosuppressive M2c-
macrophages are the outcome of IL-10, TGF-β
(transforming growth factor β), glucocorticoids or im-
mune complex rich environments. M2c macrophages gen-
erate further IL-10 and matrix-remodeling factors such as
matrix metalloproteinases (MMPs) [4, 5]. Elevated CD163
expression is a validated marker of M2c polarization [5].
TAMs, a macrophage population recruited and edu-
cated by tumor cells, which are therefore exposed to IL-
10, TGF-β, M-CSF (monocyte colony stimulating factor)
[6] and other immunosuppressive stimuli [7], are more
closely related to the M2 type [8]. In the tumor micro-
environment, TAMs will preferentially perform trophic
and immunosuppressive rather than immune effector
tasks [3, 9, 10]. Hence, TAMs promote epithelial out-
growth and invasion, which are common features of de-
velopment and cancer [3, 9]. Wickoff et al. have shown
that mammary tumors exhibit a paracrine loop between
TAMs and cancer cells. TAMs express monocyte colony
stimulating factor receptor (M-CSFR, also known as
CSF-1R or cFMS), which binds monocyte colony stimu-
lating factor (M-CSF, also known as CSF-1) secreted by
cancer cells. Conversely, TAMs secrete epidermal growth
factor (EGF) and activate the EGF receptor (EGFR) on
the cancer cells. This allows co-migration of the two cell
types, thus, enhancing motility and subsequent invasion
of healthy surrounding tissue and intravasation [11, 12].
Also, breast cancer cell leucocyte receptor, vascular cell
adhesion molecule 1 (VCAM1) binding to TAM α4-
integrin explains the increased survival of VCAM1+
tumor cells in leucocyte-rich environments [13].
Like their phenotype and interactions with tumor cells,
the location of TAMs in relation to hypoxic areas is a
key parameter controlling tumor growth. In addition to
the perivascular TAMs, which take part in cancer cell in-
vasion [11, 12], TAMs are also recruited into hypoxicareas [14]. Within these avascular areas TAMs alter their
gene expression profile, favoring a pro-tumor M2
phenotype [15]. This may explain why in the early stages
[16] of cancers of the lung [17], colon [18] and stomach
[19], the macrophages in the normoxic milieu display an
M1 phenotype and are associated with good prognosis.
Immunohistopathological breast carcinoma studies
with restricted numbers of samples (n = 53 and 120,
respectively) reveal a gradual increase in the amount of
infiltrating macrophages (CD68+) from normal breast
tissue to benign proliferative breast disease, ductal car-
cinoma in situ (DCIS) and infiltrating ductal carcinoma
[20, 21]. Two larger studies (n = 1,322 and 168, respect-
ively) confirmed that CD68+ macrophages were associ-
ated with higher tumor grade, estrogen receptor (ER)
and progesterone receptor (PR) negativity, human epi-
thelial growth factor receptor 2 (HER-2) positivity and a
basal phenotype, but led to the conclusion that CD68
expression was not an independent prognostic factor
[22, 23]. Another breast cancer cohort study (n = 144),
looking at total macrophage number (CD68+) and M2
macrophages (CD163+) found that CD163 was also asso-
ciated with other prognostic markers [24]. It showed
that CD68+ cells in the tumor stroma but not in the
tumor nest were an independent prognostic factor for
decreased cancer-specific survival, accounting for the
localization of TAMs in the tumors more than their
mere presence. Triple-negative/basal-like breast tumor
stroma had more CD163+ and CD68+ cells and a higher
proportion of CD163 relative to CD68 when compared
to the stroma of luminal A tumors. This indicates a pre-
dominance of mature M2 macrophages and possibly im-
mature myeloid-derived cells (MDCs, also CD163+) in
triple-negative disease [24].
Several clinical studies have found an association between
macrophage infiltration and angiogenesis in breast cancer
[22, 25–28]. However, in relation to prognosis it is unani-
mous that larger studies of macrophage subpopulations are
needed. This study intends to fill that gap. Focusing on the
expression of M1 and M2 markers in samples from a large
cohort of patients with breast cancer (n = 562), we looked
for possible associations with tumor progression. Addition-
ally, by studying the ex vivo differentiation of human mac-
rophages in the presence of breast cancer conditioned
media (CM), we aimed to find possible mechanisms of
TAM education. To achieve these aims, we revisited tissue
microarrays from a large cohort [29] of early human breast
tumors of different subtypes, grades and aggressiveness and
used different breast cancer cell lines.
Methods
Human samples
TMA samples (n = 562 out of 1,199 patients from
the FinXX study, NCT00114816 [29]) were studied
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the sub-cohort are described in Table 1. Formalin-fixed,
paraffin-embedded tumor samples were used for TMA.
Blocks were made using a 1.0-mm tissue cylinder
through a histologically representative area of each donor
tumor block. From each donor block, 2–4 cores were cut
and 15 TMA blocks were prepared, each containingTable 1 Patient demographics and relevant clinical characteristics
Factor Entire series CD68a Pb
≤369 >369
n = 562 n = 277 n = 274
Age, years
≤50 213 95 113
>50 349 182 161 0.093
Tumor size median
≤22 mm 283 144 132
>22 mm 278 132 142 0.348
N.A. 1
Nodal status
pN0 65 27 37
pN+ 497 250 237 0.169
Histological type
Ductal 399 181 211
Lobular 110 66 43
Other 53 30 20 0.010
Histological grade
Grade 1 46 33 13
Grade 2 264 138 119
Grade 3 250 106 140 0.001
N.A. 2
ER status
Positive 405 215 181
Negative 157 62 93 0.003
HER-2 status
Positive 170 85 83
Negative 392 192 191 0.920
Biological group
ER+, HER-2− 314 165 142
ER+, HER2+ 91 50 39
ER-, HER2+ 79 35 44
ER-, HER2− 78 27 49 0.015
Ki67
≤20 % 271 149 116
>20 % 242 104 134 0.005
N.A. 49
Results are presented as number of patients. aThe cutoff values used correspond to
test. ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, N.A. n61–84 tumor samples plus 2–3 liver samples as positive
controls.
Immunohistochemical analysis
Sections (4-μm) of the TMA blocks were stained using
standard immunohistochemical techniques for the expres-
sion of CD68 (anti-SA2 antibody clone 3C6, Abcam,CD163a Pb HLA-Drαa Pb
≤167.5 >167.5 ≤107 >107
n = 270 n = 267 n = 280 n = 275
105 98 112 100
165 169 0.602 168 175 0.378
137 129 140 138
132 138 0.545 139 137 1.000
28 33 37 28
242 234 0.468 243 247 0.267
171 213 204 192
69 33 47 60
30 21 <0.001 29 23 0.274
26 16 20 25
153 97 127 132
91 152 <0.001 131 118 0.518
214 171 191 207
56 96 <0.001 89 68 0.065
72 93 93 77
198 174 0.040 187 198 0.183
173 123 139 168
41 48 52 39
31 45 41 38
25 51 <0.001 48 30 0.032
158 96 124 140
92 144 <0.001 126 116 0.252
the median values of number of positive cells in the entire series. bChi-square
ot available
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castle, UK) and HLA-DRα (Dako, Glostrup, Denmark)
[30, 31] (detailed information provided in Additional file
1). All the stained TMA slides were scanned using an
Olympus virtual microscope equipped with Dotslide using
the 10× objective (Olympus BX51, Olympus, Munich,
Germany), and AxioCam camera (Zeiss, Jena, Germany).
Positively stained cells were counted using Fiji equipment
version 1.48s (Wayne Rasband, NIH). After color decon-
volution for hematoxylin and 3,3’-Diaminobenzidine
(DAB), the threshold was set for macrophage visualization.
The size limit for particle analysis was carefully chosen to
include only macrophages. Damaged samples were ex-
cluded from the analysis. The data were analyzed in a
double-blinded fashion. The investigators were blinded to
the identity and clinical pathological characteristics of each
sample while analyzing/scoring the macrophage content
and differentiation status. The final numbers of positive
cells per marker, per sample were passed on to hypothesis-
naïve investigators who performed the statistical analysis of
the cohort.
Cell culture
Human breast cancer cell lines MCF-7, MDA-MB231 and
T47D, obtained from American Type Culture Collection
(ATCC), were grown in Roswell Park Memorial Institure
(RPMI)-1640 medium (Sigma-Aldrich, St Louis, MO, USA)
supplemented with 10 % fetal bovine serum (FBS) (Gibco,
Grand Island, NY, USA) and 100 IU/ml penicillin and
streptomycin (Gibco, Bleiswijk, Netherlands) at 37 °C in a
5 % CO2 atmosphere. After reaching confluence, cell culture
medium was changed to medium containing only 1 % FBS
and kept in culture for 72 h. At the end of the culture period,
the CM were collected from at least three independent cell
line batches from each cell type. The CM were centrifuged
for 5 minutes at 2,800 g, aliquoted and frozen at −20 °C. CM
were used as 50 % supplement of the macrophage differenti-
ation culture medium together with 10 % FBS. The cell lines
were recently authenticated by STR (Short tandem repeat)
profiling by a certified cell line authentication service (DDC
Medical, Fisher Scientific, London, UK). Mycoplasma detec-
tion was performed on a routine basis by 4’,6-Diamidino-2-
phenylindole (DAPI) staining of cultured cells.
Peripheral blood mononuclear cell (PBMC) isolation
PBMCs from five different donors were isolated by centri-
fugation over Ficoll gradient (Sigma-Aldrich, St Louis,
MO, USA). CD14+ cells were magnetically labeled with
α-CD14 microbeads and positively selected by MACS
technology (Miltenyi Biotec, Cologne, Germany).
Macrophage differentiation
To obtain M1, M2a and M2c macrophages, CD14+ mono-
cytes were cultured in MEM (Lonza, Basel, Switzerland)supplemented with 10 % FBS (Gibco, Grand Island, NY,
USA) (control, CTR), with IFN-γ (50 ng/ml; M1), or IL-4
(50 ng/ml; M2a), or IL-10 (50 ng/ml; M2c) for 5 days with
replacement of half of the culture media at day 3 [32]. To
assess the effect of breast cancer cell-line-secreted factors,
the same differentiation protocol was carried out in the
presence or absence of 50 % CM from MDA-MB231,
MCF-7 or T47D cells. For activation status experiments
(ELISA), cells were treated with LPS (10 ng/ml, Sigma-
Aldrich, St Louis, MO, USA) for one additional day. Un-
less otherwise stated, all the used cytokines were from
R&D Systems (Minneapolis, MN, USA). Supernatants
were collected, centrifuged for 5 minutes at 2,800 g, ali-
quoted and stored at −20 °C until further analysis. Cells
were harvested with Accutase (Invitrogen, Paisley, UK),
debris were removed by centrifugation (5 minutes at
400 g), and cells were used for flow cytometry analysis.
Supernatants were used for ELISA and zymography.
Flow cytometry
Ex vivo polarized macrophages were analyzed by
validated flow cytometry methods [5], with the BD LSR
II flow cytometer (BD Biosciences, Erembodegem-Dorp,
Belgium). In brief, cells were washed with PBS 0.1 %
BSA (Sigma-Aldrich, St Louis, MO, USA) and
before staining, Fc receptors were blocked with FcR
blocking reagent (BD Biosciences, Erembodegem-Dorp,
Belgium): 0.2 × 106 cells were incubated with adequate
antibody mixes and washed prior to analysis. Surface-
marker expression was analyzed with flow cytometry
using the following fluorochrome-labeled monoclonal
antibodies: CD14-APC-Cy7 (clone61D3; eBioscience,
Paris, France), CD16-PE-Cy7 (clone DJ130c; AbD
Serotec, Kidlington, UK), CD64-AF488 (clone 10.1;
BioLegend, San Diego, CA, USA), CD200R-PE (clone
OX108; AbD Serotec, Kidlington, UK), CD163-AF647
(clone GHI/61; BD Pharmingen, Erembodegem-Dorp,
Belgium), and CD86-AF488 (clone IT2.2, BD Pharmingen,
Erembodegem-Dorp, Belgium). Equivalent amounts of
isotype-matched control antibodies and unstained cells
were included in all experiments as negative and autofluo-
rescence controls. Data were analyzed with BD FACSDiva
software, after gating on the myeloid population in the
FSC/SSC plot. Values were expressed as the percent ratio
of the median fluorescence intensity (MedFI) of the marker
of interest over the MedFI of the unstained cells.
ELISA
LPS-activated macrophage culture supernatants were
used in ELISA for quantification of h-IL-10, h-IL-8, and
h-IL-6 according to the manufacturer’s instructions
(R&D systems). h-M-CSF was quantified in breast cancer
cell line CM (Duo set, R&D systems, Minneapolis, MN,
USA).
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The potential proteolytic activity of MMPs in the superna-
tants of the obtained macrophages was determined by
zymography as previously described [33]. The stained
polyacrylamide-gelatin gels were observed with the Image
Quant RT ECL imager. Densitometry of the bands corre-
sponding to pro-MMP-9 activity (92 kDa) was performed
using Fiji equipment version 1.48s (Wayne Rasband, NIH).
Presented values are the optical densities of pro-MMP-9-
digested bands normalized to the total protein content of
the corresponding total cell lysate compared with the dens-
ity of the equivalent background area.
Statistics
TMA results were analyzed with SAS version 8.2 for Win-
dows (SAS Institute, Cary, NC, USA) using the median
values of the numbers of positive cells in the entire series
as the cutoff value. Frequency tables were analyzed using
the chi-square (χ2) test. Survival between groups was com-
pared using the Kaplan-Meier life-table method and a Cox
multivariate proportional hazards model. The log-rank test
was used to confirm the robustness of the analysis. The
subgroup analyses were performed including the macro-
phage markers, the subgroup variable, and their interaction
in the Cox model. The Mann-Whitney or Kruskal-Wallis
tests were applied when suitable. All P values are two-
sided and are not adjusted for multiple testing. Experimen-
tal data were expressed as median ± SD, unless otherwise
indicated. The Kruskal-Wallis test followed by Dunn’s post
hoc test was employed to calculate statistically significant
differences between the CTR and the various conditions,
using GraphPad Prism software.
Study approval
Permission to use the tissues from the FinXX study for re-
search purposes was provided by the Finnish Ministry of So-
cial Affairs and Health. The ethics committee at the Helsinki
University Central Hospital (Helsinki, Finland) approved the
FinXX study and the current study (permission HUS 35/13/
03/02/2015). Ethical approval for the use of peripheral blood
from healthy donors was obtained from the Nantes Univer-
sity Hospital Ethics Committee. Samples were obtained from
the Établissement Français du Sang with informed consent
(agreement reference NTS 2000–24, Avenant n°10).
Online supplemental material
A supplemental table (Additional file 1) and supplemental
figures (Additional files 2, 3, 4, 5 and 6) are available online.
Results
Clinical significance of TAM numbers and differentiation
status in breast cancer patients
To explore the clinical relevance of TAM differentiation in
breast cancer patients, we evaluated total TAM number(CD68), M1 TAM (HLA-DRα) and M2 TAM (CD163) in a
large human breast cancer TMA cohort. There was hetero-
geneity among the patients in the expression levels of the
different macrophage markers (Fig. 1). M2 macrophage
number, identified as the umber of CD163+ cells, was
strongly associated with fast proliferation (Ki67 positivity
>20 %), poor differentiation (grade 3), ER negativity and
histological ductal type (Table 2). None of the individual
markers (CD68, HLA-DRα or CD163) was on its own
strongly correlated with prognosis, recurrence-free survival
(RFS) or overall survival (Additional file 2). In the multivari-
ate Cox model for RFS, markers such as Ki67 positivity
>20 %, node positivity and primary tumor size >22 mm were
strongly significant predictive factors (p <0.001 for tumor
size and <0.01 for the other factors). In the same model
CD163 was a significant factor (p = 0.011) together with
other model covariates, such as ER negativity (Table 3).
Human breast cancer cells condition ex vivo differentiation
and activation of human macrophages
As a proof of concept, we showed that the isolated
CD14+ cells could be differentiated to M1 (high CD64,
high IL-6 secretion), M2a (high CD200R and CD86, low
IL-6 and high IL-8 secretion) and M2c macrophages
(high CD163, low IL-6 and high IL-10 secretion),
respectively, using IFN-γ, IL-4 and IL-10, thus, demon-
strating their proven [34] ex vivo plasticity (Figs. 2, 3
and 4 and Additional file 3). Considering M1 differenti-
ation in the presence of IFN-γ, none of the CM affected
the expression levels of M1 surface-markers (Additional
file 4) nor the secretion profile (data not shown).
CD14+ cells differentiated in the presence of MDA-
MB231 CM alone yielded an M2 macrophage population
(Fig. 2a-e). This result was most obvious in terms of CD86,
CD200R and CD163 expression levels (Fig. 2c-e). The differ-
entiation only in the presence of other CM retained the con-
trol phenotype features (Fig. 2a-e and Additional file 3).
Macrophages differentiated in the presence of MDA-
MB231 CM produced higher amounts of IL-6, IL-8, IL-10
(Fig. 3a-c) and MMP-9 (Fig. 3j-k) than the CTR or other
CM. That scenario remained true when the cells were con-
comitantly treated with IL-4 (Fig. 3d-f) or IL-10 (Fig. 3g-i),
except for IL-6 secretion in the latter treatment (Fig. 3g).
MDA-MB231 cells secrete large amounts of M-CSF, skewing
macrophages to an M2c-like phenotype
The strong effects of the MDA-MB231 cells led us to in-
spect all the CM for dissimilarly secreted macrophage-
differentiating factors. We saw no differences in terms of
IL-10, transforming growth factor (TGF)-β or IL-4 (data
not shown), but only MDA-MB231 cells secreted high
amounts of M-CSF (Fig. 2f ).
CD14+ cells differentiated in the presence of IL-10 and
MDA-MB231 or T47D CM (Fig. 2g-i and Additional
Fig. 1 Representative images of tissue microarray (TMA) staining revealing interpatient heterogeneous macrophage marker expression levels.
CD68 (a-d), HLA-DRIIα (e-h) and CD163 (i-l). Patient core overview (a, c, e, g, i, k, scale bars 200 μm) and a detailed view of selected
area (b, d, f, h, j, l, scale bars 50 μm). Objective amplification × 10
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when compared to cells differentiated only with IL-10
(CTR, Fig. 2g). MDA-MB231 CM significantly increased
CD163 expression levels (Fig. 2i). The macrophages
treated with IL-10 and MDA-MB231 CM secreted more
IL-8, IL-10 and MMP-9 than the CTR IL-10-treated
macrophages (Fig. 3g-k).
Human breast cancer cells affect M2a macrophage
differentiation, rendering macrophages to a mixed
M2a/M2c phenotype
When exposed to IL-4, two major macrophage subpopu-
lations arose in all the conditions: CD14lo/C16lo and
CD14hi/CD16hi (Fig. 4). In the presence of breast cancer
cell line CM, the relative percentage of each of these
subpopulations changed. Instead of a predominance of
the CD14lo/C16lo population (CTR, Fig. 4a), there was a
statistically significant inversion toward a predominance
of the CD14hi/CD16hi population (Fig. 4a), especially inthe presence of MDA-MB231 (p <0.0005) or T47D CM
(p <0.05). MCF-7 CM showed the same trend reaching
equilibrium between the two subpopulations not signifi-
cantly statistically different from the subpopulation dis-
tribution in the CTR (IL-4 alone). The detailed analysis
of the surface-markers from those subpopulations indi-
cated that MDA-MB231 and T47D CM increase CD14
(Fig. 4b) and decrease CD86 overall expression (Fig. 4j).
MDA-MB231 CM increases CD16 (Fig. 4d), CD163
(Fig. 4f ) and CD200R expression (Fig. 4h). These fluctu-
ations are mostly due to the CD14hi/CD16hi population
(Fig. 4c, e, g, i, k) and the results were statistically signifi-
cant for the global expression (Fig. 4b, d, f, h, j; p <0.05).
Although not statistically significant, MCF-7 CM in-
duced the same trend as T47D CM (Fig. 4a-k).
Only MDA-MB231 CM affected cytokine and MMP-9
secretion, reflecting the exceptionality of this cell line
(Fig. 3d-f, j, k). MDA-MB231 CM in the IL-4 condition
increased IL-10 secretion (Fig. 3f ), and increased IL-6,
Table 2 CD68+ and CD163+ cell number median values and relevant clinical characteristics
Factor N = 551 CD68+ median (range) Pa N = 537 CD163+ median (range) Pa
Histological type
Ductal 392 418 (0–3634) 384 208 (2–1772)
Lobular 109 249 (1–3113) 102 106 (3–802)
Other 50 265 (0–1397) <0.001 51 127 (4–1359) <0.001
Histological grade
Grade 1 46 240 (18–3113) 42 125 (5–524)
Grade 2 257 337 (0–3634) 250 115 (2–1229)
Grade 3 246 436 (0–2595) <0.001 243 265 (3–1772) <0.001
N.A. 2 2
ER status
Positive 396 340 (0–3634) 385 131 (2–1772)
Negative 155 435 (0–2595) 0.006 152 268 (6–1743) <0.001
HER-2 status
Positive 168 363 (9–2673) 165 221 (2–1772)
Negative 383 369 (0–3634) 0.900 372 148 (3–1359) 0.002
Biological group
ER+, HER-2− 307 334 (0–3634) 296 124 (3–1359)
ER+, HER-2+ 89 343 (12–2673) 89 200 (2–1772)
ER-, HER-2+ 79 424 (9–1306.5) 76 227 (7–1743)
ER-, HER-2− 76 484 (0–2595) 0.023 76 289 (6–1111) <0.001
Ki67
≤20 % 265 318 (0–3634) 254 115 (2–1772)
>20 % 238 431 (0–2794) 0.002 236 263 (3–1743) <0.001
N.A. 48 47
aMann-Whitney or Kruskal-Wallis test. ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, N.A. not available
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compared to MDA-MB231 CM alone, IL-4 combined
with MDA-MB231 CM decreased the secretion of IL-6,
IL-8 and MMP-9 and increased IL-10 secretion (Fig. 3a-c
and Fig. 3j, k). Overall, MDA-MB231 CM in the presence
of IL-4 produced a macrophage subpopulation with an
intermediate/mixed M2a/M2c phenotype (AdditionalTable 3 Independent prognostic factors in Cox multivariate model
Variables Regression
coefficent
Standard
error
Regression coeffic
standard error
ER+ −0.612 0.252 −2.430
HER-2+ 0.050 0.239 0.211
Ki67 >20% −0.711 0.269 −2.642
Node positivity −1.096 0.394 −2.780
Size >22 mm −0.865 0.237 −3.657
Histological grade 3 −0.071 0.268 −0.266
CD163 >167.5 0.580 0.229 2.531
ER estrogen receptor, HER-2 human epidermal growth factor receptor 2, Coef regresfile 6), with an abundant production of the immunosup-
pressive M2c-inducing cytokine IL-10. These macrophages
retain matrix-remodeling properties by secreting MMP-9.
The possibility that the MCF-7 or T47D CM-induced
CD14hi/CD16hi macrophage subpopulations also secrete
different levels of cytokines should not be discarded. Those
more subtle differences may be masked by the higher titersfor recurrence-free survival in years
ient/ χ2 P Exp (Coef) 95 % CI
Lower Upper
5.903 0.0151 0.542 0.331 0.888
0.045 0.8326 1.052 0.659 1.679
6.981 0.0082 0.491 0.290 0.832
7.730 0.0054 0.334 0.154 0.724
13.372 0.0003 0.421 0.265 0.669
0.071 0.7899 0.931 0.550 1.575
6.408 0.0114 1.786 1.140 2.798
sion coefficient, χ2 chi-squared, Exp(Coef) hazard ratio
Fig. 2 Flow cytometry analysis of CD14+ cells differentiated for 5 days with or without 50 % conditioned media (CM). a-e Percentual variation of
median fluorescence intensity (MedFI) of CD14, CD16, CD86, CD200R and CD163 compared to control (CTR), n = 5. f Monocyte colony stimulating
factor (M-CSF) protein levels in breast cancer cell line CM (n = 3). g-i Flow cytometry analysis of CD14+ cells differentiated in the presence of IL-10
for 5 days with or without 50 % breast cancer cell line CM. Percent variation of MedFI of CD14, CD16 and CD163 compared to CTR (IL-10 alone).
Error bars represent + SD, n = 5 *p <0.05, **p <0.005 (Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CM
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CD16hi subpopulations.
Discussion
Clinical significance of TAM numbers and differentiation
status in breast cancer patients
In this study CD163+ cells in primary breast tumor tis-
sue were brought up as a negative prognosis factor for
RFS. However, we could not precisely determine which
would be the additional interacting factors involved in
this effect. It is clear that CD163 correlates with known
factors to be associated with a bad prognosis, such as ER
negativity, poor differentiation (grade 3) and ductal type
(Tables 1 and 2). Previous studies have shown that
higher tumor grade [22] and higher Ki67 index are asso-
ciated with increased CD68+ macrophage infiltration in
breast tumors [23, 35]. It was suggested that highly pro-
liferative high-grade tumors elicit an active immune re-
sponse that further supports angiogenesis and tumor
growth. Further, these high-grade tumors may secrete
higher levels of macrophage-recruiting/modulating cyto-
kines such as M-CSF (ex vivo results, Fig. 2f ), IL-10
and/or TGF-β [6], which is in agreement with the highnumber of CD163+ M2-macrophages. A study exploring
stromal gene signatures in DCIS and invasive breast can-
cer found that higher grade ER-negative and PR-negative
tumors are associated with macrophage responses [36].
Macrophage infiltration was present early in the tumor
progression at the DCIS stage, and the majority of cases
remained positive in matched invasive breast cancer
cases, accounting for early macrophage recruitment in
breast cancer progression [36]. Although widely ac-
cepted as a specific monocyte/macrophage marker,
CD163 can also be expressed by immature MDCs, which
include myeloid-derived suppressor cells (MDSCs),
known to favor tumor progression [24]. Therefore, we
cannot exclude the possibility that a percentage of the
CD163+ cells detected may in fact be MDSCs, which
could account for the poor prognostic role of CD163.
Differential ex vivo conditioning of human macrophage
differentiation and activation by different breast cancer
cell types
Levano et al. [7] explored the cytokine receptor profile
of different breast cancer cell types and found
that basal-like cells (e.g., MDA-MB231) express
Fig. 3 Cytokine secretion profile after 24 h of lipopolysaccharide (LPS)-stimulation. a-c CD14+ cells differentiated for 5 days with or without 50 %
breast cancer cell line conditioned media (CM) (d-f) in the presence of IL-4 (g-i) in the presence of IL-10. a-i All results are the mean of
three experimental replicates and two biological replicates. j Representative matrix metalloproteinase (MMP)-9 zymography gel (k) relative
MMP-9 activity, expressed as digested band optical density normalized to equivalent background area optical density. Error bars represent + SD, n = 3,
*p <0.05, **p <0.005, ***p <0.0005 (Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CM; NT, non-treated
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ing factor (GM-CSF), hepatocyte growth factor receptor
(HGFR, also known as c-MET), CD44, epithelial growth
factor receptor (EGFR), transforming growth factor re-
ceptor 2 (TGFR2) and oncostatin M receptor (OSMR).
Luminal-type breast cancer cells (e.g., MCF-7 and T47D)
express RET (a proto-oncogene which encodes for a re-
ceptor tyrosine kinase for members of the glial cell line-
derived neurotrophic factor) [7] and leukemia inhibitory
factor (LIF) [37]. This suggests that TAMs have a differ-
ent influence depending on the tumor subtype, as breastcancer cells will have different receptors for TAM-
derived factors [7]. Further, mesenchymal or epithelial-
like breast cancer cells respond to or influence TAMs dif-
ferently. It has been shown that mesenchymal-like breast
cancer cells secrete GM-CSF to activate macrophages to
a CCL18-expressing TAM-like phenotype and, recipro-
cally, these TAM-like macrophages sustain the EMT of
cancer cells [38]. These findings are not totally unex-
pected when considering the role of macrophages in
mammary gland development during embryogenesis,
puberty, pregnancy and lactation. Macrophages in the
Fig. 4 Flow cytometry analysis of CD14+ cells differentiated for 5 days in the presence of IL-4 with or without 50 % conditioned media (CM).
a CD14loCD16lo and CD14hiCD16hi subpopulation distribution. b, d, f, h, j Overall percent variation of CD14, CD16, CD163, CD200R and CD86
median fluorescence intensity (MedFI), compared with control (CTR) (IL-4 alone) (c, e, g, i, k) CD14 CD16, CD163, CD200R and CD86 MedFI
percent variation in the subpopulations CD14loCD16lo and CD14hiCD16hi. Error bars represent + SD, n = 5, *p <0.05, **p <0.005, ***p <0.0005
(Kruskal-Wallis analysis followed by Dunn’s post hoc test). MB231, MDA-MB231 CM
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and activating mammary stem cells necessary for
normal morphogenesis [39], branching [9] and in the
postpartum-related influx of M2 macrophages [10]. All
these developmental processes occur via mechanisms
similar to molecular cancer mechanisms, such as vascular
endothelial growth factor A (VEGF-A)-stimulated angio-
genesis. Additionally, TAMs secrete EGF, TNF-α, VEGF
and basic fibroblast growth factor (bFGF) and havereduced antigen presenting ability. Also the release of IL-
10 by both tumor cells and TAMs immunosuppresses
cytotoxic T-lymphocytes (CTLs) [9].
A study of murine and human macrophage polarization
profiles showed that M-CSF-differentiated human macro-
phages are pro-M2, meaning that LPS or IFN-γ stimula-
tion can still induce an M1 response. However, if
stimulated with IL-4 or IL-10 they become more M2 type
than the basal macrophages [40]. M-CSF induces CD163
Sousa et al. Breast Cancer Research  (2015) 17:101 Page 11 of 14expression in macrophages which, when LPS-stimulated,
secrete higher levels of IL-12p40, TNF-α and IL-6 [34].
Our MDA-MB231 cells produce copious amounts of
M-CSF (Fig. 2f ), in levels similar to clinical samples
and MDA-MB231 cells, as reported previously [6].
Similarly, the monocyte shift toward M2/CD163+ TAMs
by increased levels of M-CSF has been seen in other
tumor types such as glioma [41], clear cell renal carcin-
oma [42], ovarian carcinoma [43] and a mouse model of
osteosarcoma [44]. In those tumor types, the elevated
M-CSF and CD163 expression correlates with higher
tumor grade [41, 42].
CD163 is a monocyte/macrophage-restricted scavenger
receptor. It clears hemoglobin/haptoglobin complexes,
hence protecting tissues from hemoglobin-induced oxi-
dative damage [45]. It was recently shown that breast
cancer CD163+ TAMs correlate with Wnt5a expression,
the latter factor being responsible for macrophage repro-
gramming to an anti-inflammatory M2 status. The same
group has reported that Wnt5a acts as a feedback antag-
onist of toll-like receptor (TLR) signaling, inducing
IL-10 secretion [26]. Our results fit this mechanism
well, as MDA-MB231 CM induced CD163 expression, a
feature of M2c TAMs. This could indicate a parallel in-
crease in Wnt5a that inhibits TLR response and increases
IL-10 secretion upon LPS stimulation (Fig. 3c, f, i).
As previously discussed, the M2c-boosted differentiation
by MDA-MB231-secreted products may have consequences
in terms of microenvironment-aided tumor progression via
immunosuppressive, matrix remodeling and scavenging
TAM functions. These effects may impair an effective im-
mune tumor rejection as our in vitro findings with murine
macrophages and breast cancer cell line CM indicate [46].
The overall decrease of CD86 expression in M2a mac-
rophages by breast cancer CM may contribute to im-
munosuppressive, tumor-promoting behavior. CD86,
also known as B7-2, is a type I transmembrane protein of
the immunoglobulin superfamily. It is a co-stimulatory
molecule expressed by antigen-presenting cells such as
dendritic cells and macrophages. Its binding to CD28 on
naïve T-cells is essential for Th2 differentiation, cytokine
secretion and induction of effector function [47].
In our system, M2a macrophages differentiated in the
presence of IL-4 and MDA-MB231 CM had the poten-
tial for increased CD200R signaling which in vivo would
indicate an immunosuppressive tumor-promoting envir-
onment. CD200R is a myeloid receptor expressed on
macrophages, granulocytes, dendritic cells and NK
(natural killer) cells [48]. CD200R signaling is known to
increase the immune activation threshold, being physio-
logically relevant in restraining inflammation [48].
CD200 ligand interaction with its receptor CD200R on
macrophages decreases TNF-α and IFN-γ secretion [49].
CD200 is expressed by cancer cells and other cell typeslike mesenchymal stem cells, thymocytes, activated T
cells, B cells and dendritic cells. Studies in different
tumor types, including breast cancer, showed that
CD200-CD200R interaction delivers an immunosup-
pressive signal. This signal directly decreases inflamma-
tory cytokine secretion by macrophages, and indirectly
increases regulatory T cells (Treg) and decreases effector
T-cell numbers, thereby promoting tumor progression by
immune evasion [50].
Limitations of the study
In the TMA analysis the median of positive cells for each
marker in all samples was used as a cutoff value and
analysis of normal breast tissue - probably carrying rest-
ing macrophages as a healthy baseline control - could
not be included. However, our study brought up differ-
ences in TAM activation status between patients rele-
vant to the disease outcome. Larger studies are thus
justified to ascertain the exact role of M2 macrophages
in disease progression.
In the ex vivo macrophage differentiation studies, the
extrapolation of the MDA-MB231 CM effects on macro-
phage differentiation to the clinical situation of triple-
negative breast cancer patients should be made with
care. MDA-MB231 is an aggressive model cell line, rele-
vant in the field as it is the parental cell line for several
metastatic sub-clones widely used in experiments in vivo
[51–53]. The MDA-MB231 cell line belongs to the
mesenchymal-like subtype, while cancer cells from
triple-negative breast tumors, which can be of seven dif-
ferent subtypes, have phenotypic diversity from epithelial
to mesenchymal characters [54]. However, we think our
study remains relevant as it shows that breast cancer
cells, regardless of their hormone receptor status and
epithelial/mesenchymal nature, secrete factors that edu-
cate macrophages toward M2 differentiation. The most
aggressive one, MDA-MB231, did it most effectively.
Further studies are needed to unveil the factors respon-
sible for the effects seen. M-CSF appears to be a key
factor in M2 TAM differentiation, as shown by others
[6, 55], but as breast cancer cell lines (MCF-7 and
T47D) that do not produce M-CSF also affected the M2
phenotype, inducing M2a differentiation, we think there
are other relevant M2 skewing factors, which our work
cannot address. The discovery of such factors is of
utmost relevance, and calls for further studies.
Conclusions
This study combines several lines of evidence for the im-
portance of TAM polarization status in breast cancer pro-
gression. For the first time, it is clear that CD163+ TAMs
associate with other known prognostic factors like fast pro-
liferation, poor differentiation and ER-negativity. CD163+
TAMs may be associated with a decrease in RFS according
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sults are to our knowledge the first demonstrating the
modulation of macrophage differentiation solely by breast
cancer cell-secreted factors, providing evidence for the
mechanisms of breast cancer macrophage education be-
hind clinical findings. Particularly, the mesenchymal-type
cell line MDA-MB231 polarizes macrophages toward a
mixed M2a/M2c status. It is therefore rational to venture
that the screening of TAM activation in breast cancer pa-
tients could be useful in predicting patients with a high
metastatic risk. The knowledge of TAM activation status
may allow the therapeutic targeting of TAMs, once TAMs
targeting/modulating agents pass clinical trials and become
widely available. These include bisphosphonates [56]; M-
CSF and M-CSFR inhibitors and targeting antibodies [57],
NCT01316822, NCT01444404; anti-macrophage migra-
tion inhibitory factor, NCT01765790 and L-MTP-PE,
NCT00631631. There is a scarcity of therapeutic options
for patients with triple-negative metastatic breast cancer,
and growing resistance to the available options biased by a
continuous focus on cancer cell targets, which are by na-
ture genetically unstable and prone to mutations. Ap-
proaches such as ours fuel a necessary paradigm change,
contributing to the notion that the immunological tumor
microenvironment should be taken into account in the de-
velopment of new multi-target cancer therapies.
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